The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

The second day of the CDDF Annual Conference 2024 brought multi-stakeholder speakers and audience together to facilitate candid dialogue on important topics in oncology. Here are the key takeaways from Session 3: Decentralized Care and Trials:

🔶 The Covid-19 pandemic has ushered in a period of rapid change. However, as we look ahead, there appears to be little indication that we will be capitalising on the lessons learned during this time.

🔶The FDA has released a draft guidance on decentralised trials. The incorporation of elements from this guidance into trials will vary depending on the context, with a focus on enhancing patient involvement and facilitating access to new medications.

🔶Various digital solutions platforms are currently in development, with a specific emphasis on patient-centricity aimed at improving the patient experience, reducing costs, and lowering carbon emissions, all while expediting project timelines.

🔶There is strong patient support for digital solutions such as wearables.

🔶 It is crucial to design technology with a focus on the perspective of patients and caregivers. The widespread acceptance of these innovations will largely depend on ensuring a positive and meaningful patient experience.

🔶It may be necessary to maintain both traditional and digital options to accommodate the diverse needs of all patients.

Stay tuned for more updates on the CDDF Annual Conference and its multi-stakeholder discussions. Collaboration is key to improve cancer treatment!

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70